WASHINGTON— The makers of a breakthrough hepatitis drug put profits before patients in pricing the $1,000 pill that's become a symbol of the excessive cost of medications, Senate investigators said Tuesday. A bipartisan report from the Senate Finance Committee concluded that California- based Gilead Sciences Inc. was focused on maximizing revenue for its...» Read More
Cost containment may spell trouble for much of the health-care sector, but Charles Boorady, healthcare providers analyst for Citigroup, says it's likely to spell success for pharmacy benefits managers.
How in the world is Merck gonna rebrand a product it has spent so much time, effort and money gearing toward females so that males will use it, too? I'm not sure, but it'll be interesting to watch if or when MRK wins Food and Drug Administration approval of Gardasil for boys/young men.
Big pharma's got big problems. That should not come as news to anyone who works for, follows or invests in the industry.
US stocks are a safer bet than their foreign counterparts now that the market has found a bottom, Bob Doll, CIO of global equities at BlackRock, told CNBC.
Clermont Wealth Strategies is 'underweight' the entire consumer discretionary sector, which includes retailers, Rob Morgan, market strategist at Clermont Wealth Strategies said.
While on the elliptical at the gym the other night I was watching one network newscast and the person on the machine next to me was watching another one.
Even before the results of the election were official there was already speculation in the blogosphere about who might become the next Commissioner of the Food and Drug Administration under a President Obama.
Drugmaker AstraZeneca, helped by currency effects and cost savings, raised its full-year earnings forecasts on Thursday as third-quarter forecasts beat expectations.
In this Web Extra the traders talk steel and pharma stocks while also paying some attention to the Fed meeting, housing numbers, and delivering a message to Bill Gates.
Pharmaceuticals are priced at a bargain, said Mike Burnick, Weiss Capital Management director of research.
You gotta feel sorry for the folks at Merck. Immediately after the drugmaker finishes a program to get rid of more than 10,000 employees, the company drops the ax again.
In this Web Extra find out how the traders are playing Boeing, the release of Google's new phone, Ma' Bell earnings and more.
Genentech investors who were hoping Roche would shed a little more light on the status of its proposed acquisition of the biotech giant might have hung up from the Swiss drugmaker's conference call a little disappointed.
U.S. companies ranging from chemicals like Du Pont, to pharmas like Pfizer and Schering Plough, and financials like Fifth Third and BlackRock, reported earnings Tuesday.
A drug stock with a safe dividend? That's just what you need in this tough environment.
As we head into the weekend (TGIF, right?), I wanted to clean out the ol' inbox.
I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.
On the Genentech third quarter earnings conference call analysts, investors and reporters were hoping to get some color on the status of the Roche play for the rest of DNA it doesn't already own.
Since there should really be no compelling reason to blog or report on Dendreon and Provenge for quite awhile, here's one last hurrah.
In my reporting, I always try to keep it simple. Particularly in the middle of the credit crisis, too much financial jargon goes over the heads of most people. The same can be said for biopharma coverage.